# 7/14 APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Center

> **NIH NIH U01** · CLEVELAND CLINIC LERNER COM-CWRU · 2024 · $271,567

## Abstract

PROJECT SUMMARY
APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Center
We submit this application in response to RFA-DK-22-506. The Cleveland Clinic and the University of Michigan
form the Clinical Center 7 which is a current member of the APOLLO Consortium. This Consortium was
established in 2017 to work seamlessly with the Association of Organ Procurement Organizations (AOPO) to
enroll participants in the largest observational study to date of kidney transplant recipients and donors to evaluate
APOL1 gene mutations in kidney donor as a risk factor for graft loss. Our Clinical Center has been a leader and
top enroller for eligible recipients and living kidney donors in the Midwest. This has been achieved through a
very close collaboration between all site PIs and research coordinators. The following transplant centers are part
of CC7: Cleveland Clinic in Cleveland, Ohio, Cleveland Clinic in Weston, Florida, University of Michigan, Saint
John’s Hospital in Detroit Michigan, Mercy Health St. Mary’s in Michigan, University of Toledo, University of
Cincinnati, Ohio State University, University Hospitals of Cleveland, University of Pittsburgh Medical Center,
SUNY Foundation/University of Buffalo, Henry Ford Health System and University of Chicago. They are
participating as engaged sites. In Phase 1 of APOLLO, we have successfully consented 281 kidney transplant
recipients and 33 living donors, with DNA on hand in 246 recipients (91%) and 33 donors (100%), across these
centers. Our site has overseen the careful collection of clinical data from the electronic medical record at our
own site and subsites to complete the APOLLO Consortium Data Forms accurately and entirely. In Phase 2, we
will continue to obtain critical follow-up data on all participants and ensure completion of data abstraction from
electronic medical records, to provide patient-level detail not available in databases maintained by United
Network for Organ Sharing (UNOS) and the Scientific Registry of Transplant Recipients (SRTR). We will ensure
a urine albumin-to-creatinine ratio is measured in all participants, at all sites, at a longitudinal follow-up time point
of at least two years from original enrollment in APOLLO Phase 1. The University of Michigan and The Cleveland
Clinic will continue to collect additional biospecimens for contribution to the biorepository as well as unstained
biopsy slides as we have been doing through Phase 1. We will work with the Scientific Data and Research Center
to ensure return of genotype results to all participants who desire this information. We will also continue to recruit
living donors at our sites. Continuation of the APOLLO Consortium will lead to important advances in our
understanding of APOL1 high-risk status and its influence on graft function as well as the biology of APOL1 gene
effects.

## Key facts

- **NIH application ID:** 10917308
- **Project number:** 5U01DK116097-07
- **Recipient organization:** CLEVELAND CLINIC LERNER COM-CWRU
- **Principal Investigator:** Mona Doshi
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $271,567
- **Award type:** 5
- **Project period:** 2017-09-25 → 2028-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10917308

## Citation

> US National Institutes of Health, RePORTER application 10917308, 7/14 APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Center (5U01DK116097-07). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10917308. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*